Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial

BACKGROUND: Tafolecimab, a fully human proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody developed for the treatment of hypercholesterolemia, demonstrated robust lipid-lowering efficacy and favorable safety in previous short-term studies. We aimed to assess the long-term effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Huo, Yong, Chen, Beijian, Lian, Qiufang, Wang, Shuqing, Liu, Lu, Lu, Di, Qu, Yanling, Zheng, Guanzhong, Li, Lipeng, Ji, Yuan, Yin, Guotian, Huang, Wenjun, Xie, Ying, Yang, Xinchun, Gao, Xiufang, An, Pei, Xue, Fengtai, Li, Haoyu, Deng, Huan, Li, Li, Pei, Lijuan, Qian, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558773/
https://www.ncbi.nlm.nih.gov/pubmed/37808342
http://dx.doi.org/10.1016/j.lanwpc.2023.100907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558773/
https://www.ncbi.nlm.nih.gov/pubmed/37808342
http://dx.doi.org/10.1016/j.lanwpc.2023.100907

Ejemplares similares